Download Image
    
Share
  
Post
Zenuzolac for COVID-19
1 study with 90 patients
Hospital Icon Control
Hospital Icon Zenuzolac Serious Outcome Risk
No significant improvements are seen in meta analysis to date.
COVID-19 Zenuzolac studies. Dec 2025. c19early.org
0 0.5 1 1.5+ All studies -200% Mortality -200% Hospitalization 1% RCTs -200% Late -200% Favorszenuzolac Favorscontrol
Zenuzolac (GLS-1027) is an oral, small molecule isoxazole immunomodulator that down-regulates NF-κB/p38-mediated pro-inflammatory cytokine production and Th17 responses.
Apr 11
 Kane et al., NCT04590547 Safety, Tolerability and Efficacy and Dose Response of GLS-1027 in the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection
200% higher mortality (p=0.34), 1% worse recovery (p=0.99), and 1% shorter hospitalization (p=0.87). RCT 132 hospitalized COVID-19 patients showing no significant difference in outcomes with zenuzolac (GLS-1027) treatment.